問卷

TPIDB > Search Result

Search Result

篩選

List

11Cases

2024-02-12 - 2028-11-18

Phase II/III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2025-03-01 - 2027-08-31

Phase II

Active
A single-therapy, multicenter, repeated-dose phase 2 trial was conducted to evaluate the safety of OBI-858 in subjects with moderate to severe frown lines.
  • Condition/Disease

    Moderate to severe frown lines

  • Test Drug

    OBI-858

Participate Sites
5Sites

Recruiting5Sites

2018-06-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2025-11-03 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2023-01-13 - 2025-12-31

Others

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-02-15 - 2025-12-15

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2019-02-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2018-09-21 - 2028-11-30

Others

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2019-04-15 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-09-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

1 2